Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells

Christian Schütz; Juan Carlos Varela; Karlo Perica; Carl Haupt; Mathias Oelke; Jonathan P. Schneck

doi:10.18632/oncotarget.26018

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells

PDF | How to cite

Oncotarget. 2018; 9:32401-32401. https://doi.org/10.18632/oncotarget.26018

Metrics: PDF 1428 views | ?

Christian Schütz^1,4, Juan Carlos Varela², Karlo Perica¹, Carl Haupt¹, Mathias Oelke^1,3 and Jonathan P. Schneck¹

¹ Institute of Cell Engineering and Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
² Division of Hematology, Department of Medicine, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland, USA
³ NexImmune Inc., Gaithersburg, Maryland, USA
⁴ Current address: Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany

Published: August 17, 2018

This article has been corrected: The correct funding information is given below:

FUNDING

This work was in part supported by German Cancer Foundation (Grant no. 70112372), German Research Foundation (SCHU 2681/1-1), HERA Women’s Cancer Foundation OSB1 Grant (C.S.) and the National Institutes of Health (P01-AI072677, R01- CA108835 and R21-CA185819), TEDCO/Maryland Innovation Initiative and Neximmune, Inc. MD Biotech Center (J.P.S.).

Original article: Oncotarget. 2016; 7:68503-68512. DOI: https://doi.org/10.18632/oncotarget.11785.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26018

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells